Recent developments in steroid-responsive pancreatitides (autoimmune pancreatitis)

Raghuwansh P. Sah, Suresh T Chari

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose of review There are two distinct steroid responsive chronic fibro-inflammatory diseases of the pancreas, called type 1 and type 2 autoimmune pancreatitis (AIP). We review recent progress in this field. Recent findings It has recently been suggested that the term AIP be used to describe type 1 AIP and the term idiopathic duct-centric chronic pancreatitis (IDCP) be used for type 2 AIP. Clinical features and long-term outcomes of AIP and IDCP are well characterized and prognosis of both diseases is excellent. Diagnostic strategies tailored to regional practice patterns have emerged with the application of International Consensus Diagnostic Criteria for AIP. Although corticosteroids remain the mainstay of treatment, management of relapses and strategies for preventing multiple relapses are better understood, including the role of maintenance therapy and B-cell depletion therapy with rituximab. Association studies with malignancies have yielded conflicting results regarding risk of cancer in AIP. Summary The treatment, follow-up guidelines and associations continue to evolve with our increasing experience with both AIP and IDCP. In AIP, rituximab can be used for both induction and maintenance of remission. IDCP responds to steroids without need for maintenance therapy. Both AIP and IDCP have excellent prognosis.

Original languageEnglish (US)
Pages (from-to)387-394
Number of pages8
JournalCurrent Opinion in Gastroenterology
Volume31
Issue number5
DOIs
StatePublished - Aug 24 2015

Fingerprint

Pancreatitis
Steroids
Chronic Pancreatitis
Remission Induction
Recurrence
Therapeutics
Cell- and Tissue-Based Therapy
Pancreas
Neoplasms
Adrenal Cortex Hormones
B-Lymphocytes
Maintenance
Guidelines

Keywords

  • Autoimmune pancreatitis
  • Chronic pancreatitis
  • Idiopathic duct-centric pancreatitis
  • Igg4-related disease
  • Lymphoplasmacytic sclerosing pancreatitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Recent developments in steroid-responsive pancreatitides (autoimmune pancreatitis). / Sah, Raghuwansh P.; Chari, Suresh T.

In: Current Opinion in Gastroenterology, Vol. 31, No. 5, 24.08.2015, p. 387-394.

Research output: Contribution to journalArticle

@article{a540631695554c438efc8c19cc498f85,
title = "Recent developments in steroid-responsive pancreatitides (autoimmune pancreatitis)",
abstract = "Purpose of review There are two distinct steroid responsive chronic fibro-inflammatory diseases of the pancreas, called type 1 and type 2 autoimmune pancreatitis (AIP). We review recent progress in this field. Recent findings It has recently been suggested that the term AIP be used to describe type 1 AIP and the term idiopathic duct-centric chronic pancreatitis (IDCP) be used for type 2 AIP. Clinical features and long-term outcomes of AIP and IDCP are well characterized and prognosis of both diseases is excellent. Diagnostic strategies tailored to regional practice patterns have emerged with the application of International Consensus Diagnostic Criteria for AIP. Although corticosteroids remain the mainstay of treatment, management of relapses and strategies for preventing multiple relapses are better understood, including the role of maintenance therapy and B-cell depletion therapy with rituximab. Association studies with malignancies have yielded conflicting results regarding risk of cancer in AIP. Summary The treatment, follow-up guidelines and associations continue to evolve with our increasing experience with both AIP and IDCP. In AIP, rituximab can be used for both induction and maintenance of remission. IDCP responds to steroids without need for maintenance therapy. Both AIP and IDCP have excellent prognosis.",
keywords = "Autoimmune pancreatitis, Chronic pancreatitis, Idiopathic duct-centric pancreatitis, Igg4-related disease, Lymphoplasmacytic sclerosing pancreatitis",
author = "Sah, {Raghuwansh P.} and Chari, {Suresh T}",
year = "2015",
month = "8",
day = "24",
doi = "10.1097/MOG.0000000000000205",
language = "English (US)",
volume = "31",
pages = "387--394",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Recent developments in steroid-responsive pancreatitides (autoimmune pancreatitis)

AU - Sah, Raghuwansh P.

AU - Chari, Suresh T

PY - 2015/8/24

Y1 - 2015/8/24

N2 - Purpose of review There are two distinct steroid responsive chronic fibro-inflammatory diseases of the pancreas, called type 1 and type 2 autoimmune pancreatitis (AIP). We review recent progress in this field. Recent findings It has recently been suggested that the term AIP be used to describe type 1 AIP and the term idiopathic duct-centric chronic pancreatitis (IDCP) be used for type 2 AIP. Clinical features and long-term outcomes of AIP and IDCP are well characterized and prognosis of both diseases is excellent. Diagnostic strategies tailored to regional practice patterns have emerged with the application of International Consensus Diagnostic Criteria for AIP. Although corticosteroids remain the mainstay of treatment, management of relapses and strategies for preventing multiple relapses are better understood, including the role of maintenance therapy and B-cell depletion therapy with rituximab. Association studies with malignancies have yielded conflicting results regarding risk of cancer in AIP. Summary The treatment, follow-up guidelines and associations continue to evolve with our increasing experience with both AIP and IDCP. In AIP, rituximab can be used for both induction and maintenance of remission. IDCP responds to steroids without need for maintenance therapy. Both AIP and IDCP have excellent prognosis.

AB - Purpose of review There are two distinct steroid responsive chronic fibro-inflammatory diseases of the pancreas, called type 1 and type 2 autoimmune pancreatitis (AIP). We review recent progress in this field. Recent findings It has recently been suggested that the term AIP be used to describe type 1 AIP and the term idiopathic duct-centric chronic pancreatitis (IDCP) be used for type 2 AIP. Clinical features and long-term outcomes of AIP and IDCP are well characterized and prognosis of both diseases is excellent. Diagnostic strategies tailored to regional practice patterns have emerged with the application of International Consensus Diagnostic Criteria for AIP. Although corticosteroids remain the mainstay of treatment, management of relapses and strategies for preventing multiple relapses are better understood, including the role of maintenance therapy and B-cell depletion therapy with rituximab. Association studies with malignancies have yielded conflicting results regarding risk of cancer in AIP. Summary The treatment, follow-up guidelines and associations continue to evolve with our increasing experience with both AIP and IDCP. In AIP, rituximab can be used for both induction and maintenance of remission. IDCP responds to steroids without need for maintenance therapy. Both AIP and IDCP have excellent prognosis.

KW - Autoimmune pancreatitis

KW - Chronic pancreatitis

KW - Idiopathic duct-centric pancreatitis

KW - Igg4-related disease

KW - Lymphoplasmacytic sclerosing pancreatitis

UR - http://www.scopus.com/inward/record.url?scp=84942514425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942514425&partnerID=8YFLogxK

U2 - 10.1097/MOG.0000000000000205

DO - 10.1097/MOG.0000000000000205

M3 - Article

VL - 31

SP - 387

EP - 394

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 5

ER -